Further research confirmed that HER-2-targeted CAR-T cells could enhance the expression level of PD-L1 on breast cancer cells, synergistically increasing the tumor-killing function of PD-L1-targeted CAR-T cells (48). The gene discussed is ERBB2; the disease is breast carcinoma.